<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010577</url>
  </required_header>
  <id_info>
    <org_study_id>BMX-04-001</org_study_id>
    <nct_id>NCT05010577</nct_id>
  </id_info>
  <brief_title>Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection</brief_title>
  <official_title>A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects With Chronic Pseudomonas Aeruginosa (PsA) Pulmonary Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BiomX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BiomX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and&#xD;
      tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas&#xD;
      aeruginosa (PsA) bacterial load in CF subjects with chronic PsA pulmonary infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the&#xD;
      safety and tolerability of BX004-A in CF subjects with chronic PsA pulmonary infection. The&#xD;
      study is divided into two parts, a single-ascending and multiple-dose phase (Part 1) and a&#xD;
      multiple dose phase (Part 2). Subjects in both parts will be included in a 6-month safety&#xD;
      follow-up. A Data Safety Monitoring Board will monitor safety in both parts. The purpose of&#xD;
      the study is to evaluate safety and tolerability of BX004-A, and whether BX004-A reduces the&#xD;
      PsA burden in the sputum of CF subjects with chronic PsA pulmonary infection. Clinically&#xD;
      stable CF subjects with a confirmed diagnosis of CF and chronic PsA pulmonary infection will&#xD;
      be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of treatment emergent adverse events following single and multiple doses of BX004-A administered by inhalation</description>
  </primary_outcome>
  <other_outcome>
    <measure>PsA burden in sputum at various timepoints</measure>
    <time_frame>1 month</time_frame>
    <description>Change in PsA colony-forming units (CFU) per gram of sputum</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Chronic Pseudomonas Aeruginosa Infection</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>BX004-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive standard dose of nebulized bacteriophage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive nebulized placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BX004-A</intervention_name>
    <description>Combination of nebulized bacteriophages targeting Pseudomonas aeruginosa</description>
    <arm_group_label>BX004-A</arm_group_label>
    <other_name>Bacteriophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nebulized placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle buffer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infection&#xD;
             receiving standard of care CF medications&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  FEV1 ≥ 40% predicted&#xD;
&#xD;
          -  Clinically stable lung disease&#xD;
&#xD;
          -  Willing and able to provide adequate sputum samples, using any method (spontaneously&#xD;
             expectorated, induced, from home or clinic) at designated study visits.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to bacteriophages or excipients in the formulation.&#xD;
&#xD;
          -  Receipt of prior bacteriophage therapy within the 6 months prior to Screening&#xD;
&#xD;
          -  Recovery of Burkholderia species from respiratory tract within 2 years prior to&#xD;
             screening&#xD;
&#xD;
          -  Currently receiving treatment for allergic bronchopulmonary aspergillosis&#xD;
&#xD;
          -  Currently receiving treatment for active infection with non-tuberculous mycobacteria&#xD;
&#xD;
          -  History of severe neutropenia&#xD;
&#xD;
          -  History of lung transplant&#xD;
&#xD;
          -  History of solid organ transplant&#xD;
&#xD;
          -  Acquired or primary immunodeficiency syndrome&#xD;
&#xD;
          -  Initiation or change in CF modulator therapy less than 3 months prior to screening&#xD;
&#xD;
          -  Pregnant or breastfeeding female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xilla Ussery, MD</last_name>
    <role>Study Director</role>
    <affiliation>BiomX, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Physician</last_name>
    <phone>203-786-6316</phone>
    <phone_ext>108</phone_ext>
    <email>xillau@biomx.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

